Company profile
ANI Pharmaceuticals, Inc.
NASDAQ: ANIP · Healthcare · Drug Manufacturers - Specialty & Generic
#163 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
82B+FH 82DQ 83GM 77SS 85
v0.1 · 65/100 weight · provisional
↑ disclosure history, Piotroski F · ↓ balance-sheet leverage, filing timeliness
Methodology →Revenue TTM
$923.7M
Rev growth YoY (TTM)
+37.0%
Net income (FY)
$78.3M
Employees
970
as of 2026-08-09
Market cap
$1.8B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$883.4M$883.4M2025
Net income$78.3M$78.3M2025
Operating income$111.1M$111.1M2025
Total assets$1.4B$1.4B2025
Liabilities$899.7M$899.7M2025
Equity$540.7M$540.7M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Sales of rare disease pharmaceutical products48%
Total Sales of Generics and Other45%
Sales of Established Brands7%
By geography
UNITED STATES96%
Non-US4%
The read
What is ANI Pharmaceuticals, Inc.’s revenue?
ANI Pharmaceuticals, Inc. booked $883.4M in FY2025 revenue, growing 44% year over year — faster than most Healthcare companies we track, at a 8.9% net margin.
Peers · Healthcare
Ionis Pharmaceuticals, Inc.71BInspire Medical Systems, Inc.78B+Neogen Corporation65BNutex Health, Inc.68BBioCryst Pharmaceuticals, Inc.76B+Harmony Biosciences Holdings, Inc.76B+Key facts
CEONikhil Lalwani
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersBaudette, MN
ExchangeNASDAQ: ANIP
Employees970
IPO date2000-05-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.